Ascendis Pharma A (ASND) Share-based Compensation (2014 - 2026)

Ascendis Pharma A has disclosed Share-based Compensation across 13 years of filings, most recently posting $35.5 million for Q1 2026.

• Share-based Compensation for Q1 2026 came in at $35.5 million, up 32.19% year-over-year; the trailing twelve-month figure through Mar 2026 was $140.2 million (up 25.78% YoY), and the FY2025 annual result was $135.2 million, up 32.49% from the prior year.
• Share-based Compensation came in at $35.5 million for Q1 2026 at Ascendis Pharma A, up from $34.9 million in the prior quarter.
• In the past five years, Share-based Compensation ranged from a high of $35.8 million in Q3 2025 to a low of $13.6 million in Q3 2022.
• The 5-year median for Share-based Compensation is $22.4 million (2022), against an average of $24.2 million.
• Across the five-year window, Share-based Compensation slumped 34.44% in 2023 and jumped 63.7% in 2024, its largest moves.
• Ascendis Pharma A's Share-based Compensation stood at $14.2 million in 2022, then grew by 20.93% to $17.1 million in 2023, then surged by 63.7% to $28.0 million in 2024, then advanced by 24.44% to $34.9 million in 2025, then rose by 1.92% to $35.5 million in 2026.
• The last three Share-based Compensation figures came in at $35.5 million (Q1 2026), $34.9 million (Q4 2025), and $35.8 million (Q3 2025), per Business Quant data.